We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · January 10, 2022

Toxicity and Clinical Outcomes in Full vs Reduced Starting-Dose Cabozantinib in Metastatic RCC

Clinical Genitourinary Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients
Clin Genitourin Cancer 2021 Nov 12;[EPub Ahead of Print], DJ Martini, ST Evans, Y Liu, JM Shabto, OE Uner, TA Olsen, JT Brown, GA Russler, L Yantorni, S Caulfield, JM Goldman, B Nazha, WB Harris, VA Master, O Kucuk, BC Carthon, MA Bilen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading